Drug Type Synthetic peptide |
Synonyms Plovamer, Plovamer acetate (USAN) + [1] |
Target |
Mechanism HLA class II antigen modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H43N5O9 |
InChIKeyBBFYAJHFKUFNCR-GPOOOTPOSA-N |
CAS Registry507277-44-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09657 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 2 | - | - | |
Multiple Sclerosis | Phase 2 | - | - |
Phase 2 | 255 | (Plovamer Acetate 0.5 Milligram (mg)) | bhleoifpby(lmthkjifoh) = mrefnldtqp othafgeyfl (djnkxobfcp, oketbauzqm - nvazgzirjs) View more | - | 11 May 2016 | ||
(Plovamer Acetate 3 mg) | bhleoifpby(lmthkjifoh) = eakqebafxk othafgeyfl (djnkxobfcp, uacwepuaca - pmhnzarqpa) View more |